Clinical trials
Adenocarcinoma trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
53 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2012 | 3 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Recruiting | 9 |
| Terminated | 9 |
| Active, not recruiting | 6 |
| Unknown status | 4 |
| Available | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Astellas Pharma Global Development, Inc. | 5 |
| Eli Lilly and Company | 3 |
| National Cancer Center, Korea | 3 |
| AstraZeneca | 2 |
| Australasian Gastro-Intestinal Trials Group | 2 |
| Blueprint Medicines Corporation | 2 |
| Boehringer Ingelheim | 2 |
| Daiichi Sankyo Co., Ltd. | 2 |
| Hoffmann-La Roche | 2 |
| Novartis Pharmaceuticals | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adenocarcinoma | 53 |
| Neoplasms | 19 |
| Carcinoma, Non-Small-Cell Lung | 14 |
| Stomach Neoplasms | 14 |
| Carcinoma | 13 |
| Lung Neoplasms | 10 |
| Neoplasms by Site | 10 |
| Digestive System Neoplasms | 8 |
| Neoplasms by Histologic Type | 8 |
| Neoplasm Metastasis | 7 |
Trials
Showing 1 to 25 of 53. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.